http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-625423-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d05175aa9dc4232d9e01d88900f7e0b6 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-347 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 |
| filingDate | 2010-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea7ca24db7f6b0097e745b0724538101 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0dbe8adc4d868f3c64acc26393040884 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b024c2600a802674b9b9c346f5fd5095 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_04c2943b6220faea349acdf2933a378e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90c4e7348f14e4ed0e8bbdb22671d6a5 |
| publicationDate | 2015-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | NZ-625423-A |
| titleOfInvention | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| abstract | Discloses An ex vivo method for evaluating renal status in a subject, said method comprising: performing a plurality of assays configured to detect both Metalloproteinase inhibitor 2 and Hyaluronic acid in one or more body fluid samples by contacting the body fluid sample(s) with molecules that bind to each of Hyaluronic acid and Metalloproteinase inhibitor 2 under conditions sufficient for such binding to occur; determining a measured concentration of each of Hyaluronic acid and Metalloproteinase inhibitor 2 from the amounts of the molecules bound thereto in the body fluid sample(s); combining the measured concentration of each of Hyaluronic acid and Metalloproteinase inhibitor 2 using a function that converts the assay results into a single composite result to thereby provide a combined concentration of Hyaluronic acid and Metalloproteinase inhibitor 2 for the subject; comparing the combined concentration of Hyaluronic acid and Metalloproteinase inhibitor 2 for the subject to a threshold concentration; and correlating the assay results to the renal status ofthe subject, comprising: (i) assigning a diagnosis that reduced or worsening renal function or an event an event associated with reduced or worsening renal function has occurred, or assigning a risk or likelihood that reduced or worsening renal function or an event an event associated with reduced or worsening renal function is likely to occur in future, when the combined concentration of Hyaluronic acid and Metalloproteinase inhibitor 2 is above the threshold concentration; or (ii) assigning a diagnosis that reduced or worsening renal function or an event associated with reduced or worsening renal function has not occurred, or assigning a risk or likelihood that reduced or worsening renal function or an event an event associated with reduced or worsening renal function is not likely to occur in future, when the combined concentration of Hyaluronic acid and Metalloproteinase inhibitor 2 is below the threshold concentration. |
| priorityDate | 2009-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 37.